Serum Level of Bioactive Mediators and Urinary Biopyrins in Psoriasis
NCT03889938 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60
Last updated 2019-03-26
Summary
1. Assess the level of lipid mediators in patients with psoriasis
2. Assess the urinary level of biopyrins as New marker of oxidative stress in patients with psoriasis
3. Correlate the serum level of bioactive lipid mediators and urinary level of biopyrins with Psoriasis Area and Severity Index
Conditions
Interventions
- DIAGNOSTIC_TEST
-
Serum and urinary assessment
Assess bioactive lipid mediators in blood and biopyrins in urine
Sponsors & Collaborators
-
Assiut University
lead OTHER
Eligibility
- Min Age
- 12 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-04-01
- Primary Completion
- 2020-04-30
- Completion
- 2020-05-31
More Related Trials
-
Cytokine Expression in Psoriasis Patients with and Without Joint Involvement
NCT05307809 ·Status: RECRUITING ·Phase: NA
-
Study to Evaluate Efficacy and Safety of MP1032 in Patients With Chronic Plaque Psoriasis
NCT03706209 ·Status: COMPLETED ·Phase: PHASE2
-
Subclinical Impairment of Cardiovascular System in Patients With Psoriasis
NCT05957120 ·Status: COMPLETED
-
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-553 in Healthy Volunteers and in Subjects With Psoriasis and Efficacy of ABBV-553 in Subjects With Psoriasis
NCT03145948 ·Status: TERMINATED ·Phase: PHASE1
-
Cross-sectional Evaluation of Biological Markers of Cardiovascular Disease in Children and Adolescents With Psoriasis
NCT01122095 ·Status: UNKNOWN
-
Premature Coronary Artery Disease (CAD) in Severe Psoriasis
NCT00893126 ·Status: COMPLETED
-
Effect of Adalimumab Therapy on Psoriasis Patient
NCT05889338 ·Status: UNKNOWN ·Phase: NA
-
Interleukin 38 as a Biomarker for Metabolic Syndrome in Psoriatic Patients
NCT05076812 ·Status: UNKNOWN
-
A Multi-center RCT Clinical Trial on Personalized Precision Medicine for Patients With Psoriasis and Psoriatic Arthritis and Investigation on Cardiovascular Biomarkers
NCT07149792 ·Status: RECRUITING ·Phase: PHASE4
-
AsseSSing Impact in pSoriatic Treatment
NCT05171270 ·Status: COMPLETED
-
Assessing the Long Term Effectiveness and Safety of Biotherapies in the Treatment of Cutaneous Psoriasis
NCT01617018 ·Status: COMPLETED
-
A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis
NCT02173301 ·Status: COMPLETED ·Phase: PHASE2
-
Regulation of Inflammatory Genes in Psoriasis
NCT03125655 ·Status: RECRUITING
-
The Association Between Psoriasis and Intestinal Bacterial Population
NCT02417792 ·Status: COMPLETED
-
A First in Human Study of AX-202 in Healthy Subjects and Patients With Psoriasis.
NCT05965089 ·Status: COMPLETED ·Phase: PHASE1
-
A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis
NCT00885196 ·Status: COMPLETED ·Phase: PHASE2
-
Understanding Participation Habits Among Plaque Psoriasis Patients
NCT06338358 ·Status: NOT_YET_RECRUITING
-
A Study of Multiple Doses of AbGn-168H by Intravenous Infusion in Patients With Moderate to Severe Chronic Plaque Psoriasis
NCT02223039 ·Status: COMPLETED ·Phase: PHASE2
-
Association Between the Occurrence of a Clinical RElapse and Gut MIcrobiota Modifications: a Cohort Study of Patients With pSOriasis
NCT06055699 ·Status: NOT_YET_RECRUITING
-
BOSTRIP: Biomarkers of Systemic Treatment Response in Psoriasis
NCT01403012 ·Status: TERMINATED
-
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-157 in Healthy Volunteers and in Participants With Chronic Plaque Psoriasis
NCT03922607 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of BMS-582949 in Patients With Moderate to Severe Plaque Psoriasis
NCT00399906 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase II Clinical Study of AC-201 Tablets in Subjects With Plaque Psoriasis
NCT06972888 ·Status: COMPLETED ·Phase: PHASE2
-
Personal Precise Treatment on Psoriasis and Psoriatic Arthritis
NCT04915105 ·Status: UNKNOWN ·Phase: NA
-
A Study to Evaluate ABY-035 in Subjects With Moderate-to-severe Plaque Psoriasis
NCT03591887 ·Status: COMPLETED ·Phase: PHASE2